Andesa Financial Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Andesa Financial Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-339	Closed	-$236K	–	144
2022 Q1	$236K	Buy	+339	New	+$214K	0.13%	135
2020 Q3	–	Sell	-345	Closed	-$213K	–	140
2020 Q2	$213K	Buy	+345	New	+$196K	0.19%	111

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Andesa Financial Management's REGN Position: Q2 2022 in Review

Andesa Financial Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 339 shares — an estimated $236K sold.

Andesa Financial Management first reported a position in REGN in Q2 2020 and held it in 2 quarters. The position peaked at $236K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Andesa Financial Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Andesa Financial Management sold 339 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $236K.
Andesa Financial Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 2 quarters.
Andesa Financial Management's Regeneron Pharmaceuticals position peaked at $236K in Q1 2022.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Andesa Financial Management's 13F filing for Q2 2022, filed 27 Jul 2022.